+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Kidney Cancer Drugs Global Market Report 2020

  • ID: 4871574
  • Report
  • December 2019
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Aveo Pharmaceuticals
  • Eisai
  • Glaxosmithkline Plc
  • NeoGenomics Laboratories
  • Prometheus Laboratories
  • MORE
Kidney Cancer Drugs Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global kidney cancer drugs market.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the kidney cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Kidney Cancer Drugs Market Global Report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market:
  • The Market Characteristics section of the report defines and explains the market.
  • The Market Size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market Segmentations break down market into sub markets.
  • The Regional and Country section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive Landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The Trends and Strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
Scope
  • Markets Covered: 1) By Type: Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) or Urothelial cell carcinoma (UCC) 2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), Proleukin (Aldesleukin), Others 3) By End Users: Hospitals, Clinics, Research Center, Others
  • Companies Mentioned: Bayer AG, Pfizer Inc, Novartis International AG, Exelixis, Inc, F. Hoffmann-La Roche Ag
  • Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time Series: Five years historic and forecast.
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Aveo Pharmaceuticals
  • Eisai
  • Glaxosmithkline Plc
  • NeoGenomics Laboratories
  • Prometheus Laboratories
  • MORE
1. Executive Summary

2. Kidney Cancer Drugs Market Characteristics

3. Kidney Cancer Drugs Market Size And Growth
3.1. Global Kidney Cancer Drugs Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Kidney Cancer Drugs Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Kidney Cancer Drugs Market Segmentation
4.1. Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Renal Cell Carcinoma (RCC)
  • Transitional Cell Carcinoma (TCC) or Urothelial cell carcinoma (UCC)
4.2. Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Nexavar (Sorafenib)
  • Sutent (Sunitinib)
  • Afinitor (Everolimus)
  • Votrient (Pazopanib)
  • Avastin (Bevacizumab)
  • Inlyta (Axitinib),
  • Torisel (Temsirolimus)
  • Proleukin (Aldesleukin)
  • Others
4.3. Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Hospitals
  • Clinics
  • Research Center
  • Other
5. Kidney Cancer Drugs Market Regional And Country Analysis
5.1. Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

6. Asia-Pacific Kidney Cancer Drugs Market
6.1. Asia-Pacific Kidney Cancer Drugs Market Overview
6.2. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.4. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

7. China Kidney Cancer Drugs Market
7.1. China Kidney Cancer Drugs Market Overview
7.2. China Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.3. China Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.4. China Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion

8. India Kidney Cancer Drugs Market
8.1. India Kidney Cancer Drugs Market Overview
8.2. India Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.3. India Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.4. India Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

9. Japan Kidney Cancer Drugs Market
9.1. Japan Kidney Cancer Drugs Market Overview
9.2. Japan Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.3. Japan Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.4. Japan Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

10. Australia Kidney Cancer Drugs Market
10.1. Australia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.2. Australia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.3. Australia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

11. Indonesia Kidney Cancer Drugs Market
11.1. Indonesia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.2. Indonesia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.3. Indonesia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

12. South Korea Kidney Cancer Drugs Market
12.1. South Korea Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.2. South Korea Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.3. South Korea Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

13. Western Europe Kidney Cancer Drugs Market
13.1. Western Europe Kidney Cancer Drugs Market Overview
13.2. Western Europe Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.3. Western Europe Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.4. Western Europe Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

14. UK Kidney Cancer Drugs Market
14.1. UK Kidney Cancer Drugs Market Overview
14.2. UK Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.3. UK Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.4. UK Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

15. Germany Kidney Cancer Drugs Market
15.1. Germany Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.2. Germany Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.3. Germany Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

16. France Kidney Cancer Drugs Market
16.5. France Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.6. France Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.7. France Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

17. Eastern Europe Kidney Cancer Drugs Market
17.1. Eastern Europe Kidney Cancer Drugs Market Overview
17.2. Eastern Europe Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.4. Eastern Europe Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

18. Russia Kidney Cancer Drugs Market
18.1. Russia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.2. Russia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.3. Russia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

19. North America Kidney Cancer Drugs Market
19.1. North America Kidney Cancer Drugs Market Overview
19.2. North America Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.3. North America Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.4. North America Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

20. USA Kidney Cancer Drugs Market
20.1. USA Kidney Cancer Drugs Market Overview
20.2. USA Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.3. USA Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.4. USA Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

21. South America Kidney Cancer Drugs Market
21.1. South America Kidney Cancer Drugs Market Overview
21.2. South America Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.3. South America Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.4. South America Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

22. Brazil Kidney Cancer Drugs Market
22.1. Brazil Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.2. Brazil Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.3. Brazil Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

23. Middle East Kidney Cancer Drugs Market
23.1. Middle East Kidney Cancer Drugs Market Overview
23.2. Middle East Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.3. Middle East Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.4. Middle East Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

24. Africa Kidney Cancer Drugs Market
24.1. Africa Kidney Cancer Drugs Market Overview
24.2. Africa Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.3. Africa Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.4. Africa Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

25. Kidney Cancer Drugs Market Competitive Landscape And Company Profiles
25.1. Kidney Cancer Drugs Market Competitive Landscape
25.2. Kidney Cancer Drugs Market Company Profiles
25.2.1. Bayer AG
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Pfizer Inc
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Novartis International AG
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Exelixis, Inc
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. F. Hoffmann-La Roche Ag
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Kidney Cancer Drugs Market

27. Kidney Cancer Drugs Market Trends And Strategies

28. Product Pipeline Analysis

29. Kidney Cancer Drugs Market Future Outlook and Potential Analysis

30. Appendix
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Aveo Pharmaceuticals
  • Eisai
  • Glaxosmithkline Plc
  • NeoGenomics Laboratories
  • Prometheus Laboratories
  • MORE
The kidney cancer drugs market consists of sales of kidney cancer drugs. It includes immunotherapy, chemotherapy and targeted therapy.

The global kidney cancer drugs market was valued at about $3.3 billion in 2018 and is expected to grow to $3.95 billion at a CAGR of 4.6% through 2022.

North America was the largest region in the kidney cancer drugs market in 2018, followed by Asia Pacific and Europe. The kidney cancer drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

Rise in incidence of renal cancer acts as one of the major drivers of the kidney cancer drugs market. Change in lifestyle of people, consumption of tobacco and unhealthy diet are some factors which contribute to the growth of these renal cancer cells. According to American Cancer Society Report 2018, an estimated 65,340 new cases of kidney (renal) cancer were diagnosed in the US in 2018 and in 2014, the estimation was around 63,920 new cases. Thus, driving the growth of the kidney cancer drugs market.

Increasing use of biologics and targeted therapies acts as a restraint for the kidney cancer drugs market. When kidney cancer is spread to other organs, targeted therapies are used to control kidney cancer where chemical drugs are ineffective. Also, targeted drugs are used post kidney cancer surgery to prevent re-occurrence of kidney cancer. Conventional chemical drugs cannot be used in the same way. Also, targeted therapies for kidney cancer has illustrated higher efficiency than normal chemical drug-based chemotherapy in random clinical trials. In a study conducted by Pfizer, using targeted therapy had more chances of tumor shrinkage than using chemical drugs. Targeted drug, axitinib and Pembrolizumab are being used to treat stage IV kidney cancer which specially attacks the spreading points of cancer. Thus, pharmaceutical industry is embracing the targeted therapies because of the above-mentioned benefits. Therefore, hindering the growth of the kidney cancer drugs market.

Use of combination therapy is trending in the kidney (renal) cancer drugs market. Combination therapy combines the effects of various drugs thereby reducing the likelihood of cancer resistant cells from developing. The improved understanding about renal cancer causes and effects has led to the discovery of combination therapy. Under this treatment the drugs from vascular endothelial growth factor (VEGF), which stimulate the protein in the blood are combined with inhibitors of mammalian target of rapamycin (mTor), which helps promote cellular biogenesis. According to a study conducted by National cancer institute (NIH) in 2019, the combination treatment leads to better outcomes in the patients suffering from advanced kidney cancer. In April 2019, Merck attained food and drug administration (FDA) approval to combine their drug Pembrolizumab, which enhances the patients’ immune system along with Pfizer’s drug Axitinib, which prevents the spread of renal cancer, this combination of drugs can help increase the pace of the patients’ recovery in advanced kidney cancer.

The kidney cancer drugs market is governed by regulatory framework of agencies such as Food and Administration Agency (FDA) and American Society of Clinical Oncology (ASCO). FDA's recommendation for kidney cancer drugs industry in the form of guidelines are mentioned within the CFR 's (Code for Federal Regulations) title number 21 under part 312, that contains sub-parts from sub part 'A' to sub part 'I'. The sub-part 'E' deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening and illnesses such as kidney cancer. The sub part 'E' also includes guidelines for the monitoring and evaluation of clinical trials of kidney cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All companies operating in kidney cancer drugs industry are required to abide to the regulations under FDA.

In October 2018, Novartis International AG, a Swiss multinational pharmaceutical company acquired Endocyte for $2.1 billion. With this acquisition, Novartis will expand Radioligand Therapy (RLT) platform with both a potential near-term product launch and early-stage clinical development programmes. Endocyte, a US-based biopharmaceutical company develops targeted therapies for the treatment of cancer and inflammatory diseases.

Major players in the market are Bayer AG, Pfizer Inc, Novartis International AG, Exelixis, Inc, F. Hoffmann-La Roche Ag
Note: Product cover images may vary from those shown
5 of 5
  • Bayer AG
  • Pfizer Inc
  • Novartis International AG
  • Exelixis Inc
  • F. Hoffmann-La Roche Ag
  • Genentech Inc.
  • Glaxosmithkline Plc
  • Active Biotech
  • Amgen
  • Thermo Fisher Scientific Inc
  • Bristol-Myers Squibb
  • Eisai
  • Roche
  • Cipla Limited
  • Onyx
  • Abbott Laboratories
  • Aveo Pharmaceuticals
  • Immatics Biotechnologies
  • Prometheus Laboratories
  • Argos Therapeutics
  • Myriad Genetics Inc
  • NeoGenomics Laboratories
  • NanoString Technologies Inc
  • Sysmex Corporation
  • Rosetta Genomics
  • Illumina Inc
  • Quest Diagnostics Incorporated
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll